[Cortical blindness during treatment with cyclosporin].

Abstract

A 40-year-old man developed cortical blindness during cyclosporin treatment shortly after an allogeneic bone marrow transplantation for chronic myeloid leukaemia. At that time the patient had a therapeutic cyclosporin blood level (226 ng/ml), but a low serum magnesium level and a marginally decreased serum cholesterol level. In addition the patient had hypertension, headache and paraesthesia in the oral, palmar and plantar areas. Vision was fully recovered after discontinuation of the cyclosporin treatment and correction of the hypomagnesaemia. Eighteen cases of cortical blindness during cyclosporin treatment are now known in the literature. Hypomagnesaemia appears to be implicated in the pathogenesis.

• Authors: L T Vlasveld, J J Cornelissen, P L Dellemijn, M V Joosse, M J van den Bent
• Journal: Nederlands tijdschrift voor geneeskunde (Ned Tijdschr Geneeskd) Vol. 138 Issue 41 Pg. 2057-61 (Oct 08 1994) ISSN: 0028-2162 [Print] Netherlands
• Vernacular Title: Corticale blindheid tijdens behandeling met ciclosporine.
• PMID: 7935970 (Publication Type: Case Reports, English Abstract, Journal Article, Review)

Chemical References

• Cyclosporins

Topics

• Adult
• Blindness (chemically induced, physiopathology)
• Bone Marrow Transplantation
• Brain (metabolism)
• Cyclosporins (adverse effects)
• Humans
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (therapy)
• Magnesium Deficiency (chemically induced, complications)
• Magnetic Resonance Imaging
• Male
• Visual Fields